UAB Sees Opportunity with Precision Medicine
Precision medicine is changing the way doctors treat people with cancer. It’s an emerging field that is sometimes referred to as “personalized medicine.” That’s because treatments are tailored for specific patient traits. Many observers say UAB is particularly well-positioned to lead the targeted therapy front. That’s the subject of the cover article in Friday’s Birmingham Business Journal. Editor Ty West talked with WBHM’s Andrew Yeager.
Interview Highlights
What precision medicine is:
“In terms of cancer care, this is a very precise form of medicine that depends a lot on the human genome and the sequencing that’s happened in recent years. It basically allows you to develop a personalized plan of care based on a patient’s DNA. This is an area that’s grown exponentially really over the past five or six years and it is an area that many believe is going to be the next frontier in medicine overall, but particularly in terms of cancer care.”
Why UAB is positioned to ride this new technology:
“They’ve already kind of been at the forefront. They’ve made some strategic hires. If you look back over the past five or six years, they’ve hired some leading experts in precision medicine and genomic medicine, so that’s one reason. If think if you look at Alabama also and our health situation here in the state, experts have told us over the years that also creates some opportunities from some interesting clinical trials. A lot of groundbreaking cancer research can be done and that’s unfortunate for our community that we’re faced with some of those chronic health challenges, but it does create opportunities to change the world here in Birmingham.”
What the university plans to do:
“They want to do a $70 million genomic medicine building. That would be a wholesale renovation of an existing building. They’re approaching this like an economic development project, not like another building at UAB’s campus. They believe with a facility like this that could be kind of a leading global facility, it’ll make it easier to recruit researchers here. And every one of those researchers are kind of like a small business. They have staffs. They have million dollar budgets that are coming in. That’s bringing money into this community. But perhaps more importantly, it’s creating the opportunity to create more jobs down the road in terms of commercialization, in terms of spinning off some startups.”
Editorial note: UAB holds WBHM’s broadcast license, but WBHM’s news and business departments operate independently.
Epstein files fallout takes down elite figures in Europe, while U.S. reckoning is muted
Unlike in Europe, officials in the U.S. with ties to Epstein have largely held their positions of power.
Four people on NASA’S Crew-12 arrive at the International Space Station
The crew will spend the next eight months conducting experiments to prepare for human exploration beyond Earth's orbit.
American speedskater Jordan Stolz wins second Olympic gold with 500-meter race victory
With the win, Stolz joins Eric Heiden as the only skaters to take gold in both the 500 and 1,000 at the same Olympics.
US military reports a series of airstrikes against Islamic State targets in Syria
The U.S. military says the strikes were carried out in retaliation of the December ambush that killed two U.S. soldiers and one American civilian interpreter.
5 European nations say Alexei Navalny was poisoned and blame the Kremlin
In a joint statement, the foreign ministries of the U.K., France, Germany, Sweden and the Netherlands say Navalny was poisoned by Russia with a lethal toxin derived from the skin of poison dart frogs.
It’s a dangerous complication of pregnancy — but a new drug holds promise
Researchers celebrate early results of a drug that may become the first treatment for a serious complication of pregnancy called preeclampsia. It's got the potential to save many lives.
